102 related articles for article (PubMed ID: 21550799)
21. Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer.
Amato RJ; Flaherty AL; Stepankiw M
Clin Genitourin Cancer; 2012 Mar; 10(1):26-31. PubMed ID: 22169794
[TBL] [Abstract][Full Text] [Related]
22. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.
Antoun S; Birdsell L; Sawyer MB; Venner P; Escudier B; Baracos VE
J Clin Oncol; 2010 Feb; 28(6):1054-60. PubMed ID: 20085939
[TBL] [Abstract][Full Text] [Related]
23. Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma.
Kasibhatla M; Steinberg P; Meyer J; Ernstoff MS; George DJ
Clin Genitourin Cancer; 2007 Mar; 5(4):291-4. PubMed ID: 17553211
[TBL] [Abstract][Full Text] [Related]
24. Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
Iguchi M; Matsumoto M; Hojo K; Wada T; Matsuo Y; Arimura A; Abe K
Jpn J Clin Oncol; 2009 May; 39(5):303-9. PubMed ID: 19336449
[TBL] [Abstract][Full Text] [Related]
25. Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib.
Zhang HL; Zhu Y; Wang CF; Yao XD; Zhang SL; Dai B; Shen YJ; Zhu YP; Shi GH; Ye DW
Int J Urol; 2011 Jun; 18(6):422-30. PubMed ID: 21481012
[TBL] [Abstract][Full Text] [Related]
26. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
McDermott DF; Sosman JA; Gonzalez R; Hodi FS; Linette GP; Richards J; Jakub JW; Beeram M; Tarantolo S; Agarwala S; Frenette G; Puzanov I; Cranmer L; Lewis K; Kirkwood J; White JM; Xia C; Patel K; Hersh E
J Clin Oncol; 2008 May; 26(13):2178-85. PubMed ID: 18445842
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study.
Zhang HL; Qin XJ; Wang HK; Gu WJ; Ma CG; Shi GH; Zhou LP; Ye DW
Oncotarget; 2015 Nov; 6(34):36870-83. PubMed ID: 26472104
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
Bilaç C; Müezzinoğlu T; Ermertcan AT; Kayhan TC; Temeltaş G; Oztürkcan S; Temiz P
Cutan Ocul Toxicol; 2009; 28(2):90-2. PubMed ID: 19514932
[TBL] [Abstract][Full Text] [Related]
29. Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma.
Shirotake S; Yasumizu Y; Ito K; Masunaga A; Ito Y; Miyazaki Y; Hagiwara M; Kanao K; Mikami S; Nakagawa K; Momma T; Masuda T; Asano T; Oyama M; Tanaka N; Mizuno R; Oya M
Clin Genitourin Cancer; 2016 Dec; 14(6):e575-e583. PubMed ID: 27102405
[TBL] [Abstract][Full Text] [Related]
30. Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation.
Miyake H; Kurahashi T; Yamanaka K; Kondo Y; Takenaka A; Inoue TA; Fujisawa M
BJU Int; 2010 Dec; 106(11):1643-7. PubMed ID: 20553261
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
Bukowski RM; Stadler WM; McDermott DF; Dutcher JP; Knox JJ; Miller WH; Hainsworth JD; Henderson CA; Hajdenberg J; Kindwall-Keller TL; Ernstoff MS; Drabkin HA; Curti BD; Chu L; Ryan CW; Hotte SJ; Xia C; Cupit L; Figlin RA
Oncology; 2010; 78(5-6):340-7. PubMed ID: 20733337
[TBL] [Abstract][Full Text] [Related]
32. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW
Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
[TBL] [Abstract][Full Text] [Related]
33. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.
Hutson TE; Bellmunt J; Porta C; Szczylik C; Staehler M; Nadel A; Anderson S; Bukowski R; Eisen T; Escudier B;
Eur J Cancer; 2010 Sep; 46(13):2432-40. PubMed ID: 20656473
[TBL] [Abstract][Full Text] [Related]
34. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis.
Jonasch E; Corn P; Pagliaro LC; Warneke CL; Johnson MM; Tamboli P; Ng C; Aparicio A; Ashe RG; Wright JJ; Tannir NM
Cancer; 2010 Jan; 116(1):57-65. PubMed ID: 19862815
[TBL] [Abstract][Full Text] [Related]
35. Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression.
Takeuchi A; Shiota M; Tatsugami K; Yokomizo A; Eto M; Inokuchi J; Kuroiwa K; Kiyoshima K; Naito S
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1557-64. PubMed ID: 21544629
[TBL] [Abstract][Full Text] [Related]
36. Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome.
Sadeghi S; Albiges L; Wood LS; Black SL; Gilligan TD; Dreicer R; Garcia JA; Escudier BJ; Rini BI
Cancer; 2012 Jul; 118(13):3277-82. PubMed ID: 22139966
[TBL] [Abstract][Full Text] [Related]
37. High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.
Wang X; Zhang L; Goldberg SN; Bhasin M; Brown V; Alsop DC; Signoretti S; Mier JW; Atkins MB; Bhatt RS
J Transl Med; 2011 Dec; 9():220. PubMed ID: 22188900
[TBL] [Abstract][Full Text] [Related]
38. High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy.
Shao YY; Lin ZZ; Chen TJ; Hsu C; Shen YC; Hsu CH; Cheng AL
Oncology; 2011; 81(2):98-103. PubMed ID: 21986371
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib.
Szmit S; Zaborowska M; Waśko-Grabowska A; Żołnierek J; Nurzyński P; Filipiak KJ; Opolski G; Szczylik C
Kidney Blood Press Res; 2012; 35(6):468-76. PubMed ID: 22688785
[TBL] [Abstract][Full Text] [Related]
40. Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus.
Lee CK; Marschner IC; Simes RJ; Voysey M; Egleston B; Hudes G; de Souza P
Clin Cancer Res; 2012 Jun; 18(11):3188-96. PubMed ID: 22472176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
